Applied Clinical Trials
Industry news focusing on the people and organizations who work in the clinical trials profession.
• Drug Safety Alliance, Inc., (Research Triangle Park, NC) a pharmacovigilance services provider, has announced the addition of industry veteran Michael Pierce, MBA, RAC, as Chief Compliance Officer. In his new role, Pierce will oversee DSA's Quality and Regulatory Compliance and Risk Management teams. Pierce has more than 35 years of government and industry experience in regulatory and quality compliance.
Michael Pierce
• ACM Global Central Lab (Rochester, NY) announced that Mark Engelhart has joined the executive management team as Chief Commercial Officer. Engelhart will be responsible for leading business development, proposals and contracts, marketing, and sales activities worldwide. Prior to joining ACM Global, Engelhart was Chief Commercial Officer at Cryoport, Inc. a provider of leading-edge cold chain logistics services.
Mark Engelhart
• ICON (Dublin, Ireland)has made two senior appointments in Early Phase and Epidemiology & Risk Management departments. Pui Man Leung, MD, has joined ICON as Senior Clinical Research Physician at the Clinical Pharmacology Unit in Manchester, UK. Leung joins the company with over 23 years of hospital and pharmaceutical industry experience in a variety of medical specialties including diabetes, endocrinology, and general medicine. Susan Anton has been appointed Director, Epidemiology and Risk Management Practice, ICON Late Phase & Outcomes Research. Anton has over 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives.
• Camargo Pharmaceutical Services (Cincinnati, OH), an end-to-end drug development service provider specializing in the 505(b)(2) process, has appointed K. Gary Barnette as Vice President of Drug Development. Barnette will be responsible for the growth of the company and excellent customer service utilizing his experience within the drug development industry and his knowledge of FDA regulations. He will be stationed in the Durham, NC office.
K. Gary Barnette
• Nathalie Doize has joined REGISTRAT-MAPI (Lyon, France) as Vice President, Clinical Operations for REGISTRAT-MAPI EU. Working as a key member of the organization's executive leadership, Doize will assume responsibilities for clinical operations in Europe and affiliated territories. She will be responsible for the strategic development and functioning of international operations to ensure that growth, profitability, quality, and customer service goals are achieved.
Correction: In the July news section, the article "Managing Budgets in Complex Times with Tight Variances" was published with inaccuracies. Please visit www.appliedclinicaltrialsonline.com/budgets for the correct version.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.